Gene-based vaccines and immunotherapeutic strategies against neurodegenerative diseases: Potential utility and limitations

References

• Plotkin SA, Plotkin SL. The development of vaccines: how the past led to the future. Nat Reviews Microbiol 2011; 9:889-93; PMID:21963800; http://dx.doi.org/10.1038/nrmicro2668
   PubMed Web of Science ®Google Scholar
• Butterfield LH. Cancer vaccines. Bmj 2015; 350:h988; PMID:25904595; http://dx.doi.org/10.1136/bmj.h988
   PubMed Web of Science ®Google Scholar
• Federoff HJ. Development of vaccination approaches for the treatment of neurological diseases. J Compar Neurol 2009; 515:4-14; PMID:19399901; http://dx.doi.org/10.1002/cne.22034
   PubMed Web of Science ®Google Scholar
• Wisniewski T, Goni F. Immunotherapeutic Approaches for Alzheimer's Disease. Neuron 2015; 85:1162-76; PMID:25789753; http://dx.doi.org/10.1016/j.neuron.2014.12.064
   PubMed Web of Science ®Google Scholar
• Solomon B, Frenkel D. Immunotherapy for Alzheimer's disease. Neuropharmacology 2010; 59:303-9; PMID:20388523; http://dx.doi.org/10.1016/j.neuropharm.2010.04.004
   PubMed Web of Science ®Google Scholar
• Ugen KE, Lin X, Bai G, Liang Z, Cai J, Li K, Song S, Cao C, Sanchez-Ramos J. Evaluation of an alpha synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease. Hum Vaccin Immunother 2015; 11:922-30; PMID:25714663; http://dx.doi.org/10.1080/21645515.2015.1012033
   PubMed Web of Science ®Google Scholar
• Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011; 377:1019-31; PMID:21371747; http://dx.doi.org/10.1016/S0140-6736(10)61349-9
   PubMed Web of Science ®Google Scholar
• Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, Gorantla S, Nemachek C, Green SR, Przedborski S, Gendelman HE. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2004; 101:9435-40; PMID:15197276; http://dx.doi.org/10.1073/pnas.0400569101
   PubMed Web of Science ®Google Scholar
• Ha D, Stone DK, Mosley RL, Gendelman HE. Immunization strategies for Parkinson's disease. Parkinsonism Relat Disord 2012; 18 Suppl 1:S218-21; PMID:22166440; http://dx.doi.org/10.1016/S1353-8020(11)70067-0
   PubMedGoogle Scholar
• Jindal H, Bhatt B, Sk S, Singh Malik J. Alzheimer disease immunotherapeutics: then and now. Hum Vaccin Immunother 2014; 10:2741-3; PMID:25483498; http://dx.doi.org/10.4161/21645515.2014.970959
   PubMed Web of Science ®Google Scholar
• Lambracht-Washington D, Rosenberg RN. Advances in the development of vaccines for Alzheimer's disease. Discov Med 2013; 15:319-26; PMID:23725605
   PubMed Web of Science ®Google Scholar
• Morgan D. Immunotherapy for Alzheimer's disease. J Inter Med 2011; 269:54-63; PMID:21158978; http://dx.doi.org/10.1111/j.1365-2796.2010.02315.x
   PubMed Web of Science ®Google Scholar
• Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408:982-5; PMID:11140686; http://dx.doi.org/10.1038/35050116
   PubMed Web of Science ®Google Scholar
• Romero-Ramos M, von Euler Chelpin M, Sanchez-Guajardo V. Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance? Hum Vaccin Immunother 2014; 10:852-67; PMID:24670306; http://dx.doi.org/10.4161/hv.28578
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-7; PMID:10408445; http://dx.doi.org/10.1038/22124
   PubMed Web of Science ®Google Scholar
• Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis. Annu Revi Pathol 2011; 6:193-222; PMID:21034221; http://dx.doi.org/10.1146/annurev-pathol-011110-130242
   PubMed Web of Science ®Google Scholar
• Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012; 11:597-604; PMID:22677258; http://dx.doi.org/10.1016/S1474-4422(12)70140-0
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64:1553-62; PMID:15883316; http://dx.doi.org/10.1212/01.WNL.0000159740.16984.3C
   PubMed Web of Science ®Google Scholar
• Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372:216-23; PMID:18640458; http://dx.doi.org/10.1016/S0140-6736(08)61075-2
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61:46-54; PMID:12847155; http://dx.doi.org/10.1212/01.WNL.0000073623.84147.A8
   PubMed Web of Science ®Google Scholar
• Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer WF, Stewart GR, Shafer LL. Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci U S A 2009; 106:4501-6; PMID:19246392; http://dx.doi.org/10.1073/pnas.0813404106
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370:322-33; PMID:24450891; http://dx.doi.org/10.1056/NEJMoa1304839
   PubMed Web of Science ®Google Scholar
• Panza F, Logroscino G, Imbimbo BP, Solfrizzi V. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? Curr Opin Psychiat 2014; 27:128-37; PMID:24445401; http://dx.doi.org/10.1097/YCO.0000000000000041
   PubMed Web of Science ®Google Scholar
• Castillo-Carranza DL, Guerrero-Munoz MJ, Sengupta U, Hernandez C, Barrett AD, Dineley K, Kayed R. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model. J Neurosci 2015; 35:4857-68; PMID:25810517; http://dx.doi.org/10.1523/JNEUROSCI.4989-14.2015
   PubMed Web of Science ®Google Scholar
• Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimer's Res Ther 2014; 6:44; PMID:25478017; http://dx.doi.org/10.1186/alzrt278
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 1998; 95:6469-73; PMID:9600990; http://dx.doi.org/10.1073/pnas.95.11.6469
   PubMed Web of Science ®Google Scholar
• Shahaduzzaman M, Nash K, Hudson C, Sharif M, Grimmig B, Lin X, Bai G, Liu H, Ugen KE, Cao C, et al. Anti-human alpha-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-alpha-synuclein rat model of Parkinson's disease. PloS One 2015; 10:e0116841; PMID:25658425; http://dx.doi.org/10.1371/journal.pone.0116841
   PubMed Web of Science ®Google Scholar
• Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci 2014; 34:9441-54; PMID:25009275; http://dx.doi.org/10.1523/JNEUROSCI.5314-13.2014
   PubMed Web of Science ®Google Scholar
• Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PloS One 2011; 6:e19338; PMID:21559417; http://dx.doi.org/10.1371/journal.pone.0019338
   PubMed Web of Science ®Google Scholar
• Tran HT, Chung CH, Iba M, Zhang B, Trojanowski JQ, Luk KC, Lee VM. Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep 2014; 7:2054-65; PMID:24931606; http://dx.doi.org/10.1016/j.celrep.2014.05.033
   PubMed Web of Science ®Google Scholar
• Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008; 42:219-32; PMID:19066740; http://dx.doi.org/10.1007/s12026-008-8076-3
   PubMed Web of Science ®Google Scholar
• Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines 2014; 2:624-41; http://dx.doi.org/10.3390/vaccines2030624
   PubMedGoogle Scholar
• Choi Y, Chang J. Viral vectors for vaccine applications. Clin Exp Vaccine Res 2013; 2:97-105; PMID:23858400; http://dx.doi.org/10.7774/cevr.2013.2.2.97
   PubMedGoogle Scholar
• Fan DS, Ogawa M, Fujimoto KI, Ikeguchi K, Ogasawara Y, Urabe M, Nishizawa M, Nakano I, Yoshida M, Nagatsu I, et al. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum Gene Ther 1998; 9:2527-35; PMID:9853519; http://dx.doi.org/10.1089/hum.1998.9.17-2527
   PubMed Web of Science ®Google Scholar
• Mouri A, Noda Y, Hara H, Mizoguchi H, Tabira T, Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J 2007; 21:2135-48; PMID:17341681; http://dx.doi.org/10.1096/fj.06-7685com
   PubMed Web of Science ®Google Scholar
• Hara H, Monsonego A, Yuasa K, Adachi K, Xiao X, Takeda S, Takahashi K, Weiner HL, Tabira T. Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheimer's Dis 2004; 6:483-8; PMID:15505369
   PubMed Web of Science ®Google Scholar
• Chen Z, Yang Y, Yang X, Zhou C, Li F, Lei P, Zhong L, Jin X, Peng G. Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease. Neurol Sci 2013; 34:1559-70; PMID:23354599; http://dx.doi.org/10.1007/s10072-012-1284-6
   PubMed Web of Science ®Google Scholar
• Davtyan H, Bacon A, Petrushina I, Zagorski K, Cribbs DH, Ghochikyan A, Agadjanyan MG. Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines. Hum Vaccin Immunother 2014; 10:1248-55; PMID:24525778; http://dx.doi.org/10.4161/hv.27882
   PubMed Web of Science ®Google Scholar
• Lambracht-Washington D, Rosenberg RN. Active DNA Abeta42 vaccination as immunotherapy for Alzheimer disease. Transl Neurosci 2012; 3:307-13; PMID:23741624; http://dx.doi.org/10.2478/s13380-012-0037-6
   PubMed Web of Science ®Google Scholar
• Young JL, Dean DA. Electroporation-mediated gene delivery. Adv Genet 2015; 89:49-88; PMID:25620008; http://dx.doi.org/10.1016/bs.adgen.2014.10.003
   PubMed Web of Science ®Google Scholar
• Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol 2013; 4:354; PMID:24204366; http://dx.doi.org/10.3389/fimmu.2013.00354
   PubMed Web of Science ®Google Scholar
• Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26:5896-903; PMID:19029422; http://dx.doi.org/10.1200/JCO.2007.13.9048
   PubMed Web of Science ®Google Scholar
• Heller LC, Ugen K, Heller R. Electroporation for targeted gene transfer. Expert Opin Drug Delivery 2005; 2:255-68; PMID:16296752; http://dx.doi.org/10.1517/17425247.2.2.255
   PubMedGoogle Scholar
• Qu B, Rosenberg RN, Li L, Boyer PJ, Johnston SA. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol 2004; 61:1859-64; PMID:15596606; http://dx.doi.org/10.1001/archneur.61.12.1859
   PubMed Web of Science ®Google Scholar
• Lambracht-Washington D, Qu BX, Fu M, Anderson LD, Jr., Stuve O, Eagar TN, Rosenberg RN. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. Cell Mol Neurobiol 2011; 31:867-74; PMID:21625960; http://dx.doi.org/10.1007/s10571-011-9680-7
   PubMed Web of Science ®Google Scholar
• Lambracht-Washington D, Qu BX, Fu M, Anderson LD, Jr., Eagar TN, Stuve O, Rosenberg RN. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Abeta42 DNA vaccine for Alzheimer disease. J Neuroimmunol 2013; 254:63-8; PMID:23036592; http://dx.doi.org/10.1016/j.jneuroim.2012.09.008
   PubMed Web of Science ®Google Scholar
• Fernandez-Borges N, Brun A, Whitton JL, Parra B, Diaz-San Segundo F, Salguero FJ, Torres JM, Rodriguez F. DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. J Virol 2006; 80:9970-6; PMID:17005675; http://dx.doi.org/10.1128/JVI.01210-06
   PubMed Web of Science ®Google Scholar
• Liu S, Shi D, Wang HC, Yu YZ, Xu Q, Sun ZW. Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice. Sci Rep 2015; 5:7771; PMID:25586780; http://dx.doi.org/10.1038/srep07771
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Cao C, Bai Y, Dong H, Choe PY, Saulino V, McLaughlin L, Whelan A, Choo AY, Weiner DB, et al. Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice. Vaccine 2006; 24:4630-9; PMID:16157426; http://dx.doi.org/10.1016/j.vaccine.2005.08.036
   PubMed Web of Science ®Google Scholar
• Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012; 11:241-9; PMID:22305802; http://dx.doi.org/10.1016/S1474-4422(12)70015-7
   PubMed Web of Science ®Google Scholar
• Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481:81-4; http://dx.doi.org/10.1038/nature10660
   PubMed Web of Science ®Google Scholar
• Ryan DA, Mastrangelo MA, Narrow WC, Sullivan MA, Federoff HJ, Bowers WJ. Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol Ther 2010; 18:1471-81; PMID:20551911; http://dx.doi.org/10.1038/mt.2010.111
   PubMed Web of Science ®Google Scholar
• Shimada M, Abe S, Takahashi T, Shiozaki K, Okuda M, Mizukami H, Klinman DM, Ozawa K, Okuda K. Prophylaxis and treatment of Alzheimer's disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein. PloS One 2013; 8:e57606; PMID:23555563; http://dx.doi.org/10.1371/journal.pone.0057606
   PubMed Web of Science ®Google Scholar
• Wang YJ, Gao CY, Yang M, Liu XH, Sun Y, Pollard A, Dong XY, Wu XB, Zhong JH, Zhou HD, et al. Intramuscular delivery of a single chain antibody gene prevents brain Abeta deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain Behav Immun 2010; 24:1281-93; PMID:20595065; http://dx.doi.org/10.1016/j.bbi.2010.05.010
   PubMed Web of Science ®Google Scholar
• Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci 2006; 26:11923-8; PMID:17108166; http://dx.doi.org/10.1523/JNEUROSCI.2795-06.2006
   PubMed Web of Science ®Google Scholar
• Tjelle TE, Corthay A, Lunde E, Sandlie I, Michaelsen TE, Mathiesen I, Bogen B. Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther 2004; 9:328-36; PMID:15006599; http://dx.doi.org/10.1016/j.ymthe.2003.12.007
   PubMed Web of Science ®Google Scholar
• Muthumani K, Flingai S, Wise M, Tingey C, Ugen KE, Weiner DB. Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab. Hum Vaccin Immunother 2013; 9:2253-62; PMID:24045230; http://dx.doi.org/10.4161/hv.26498
   PubMed Web of Science ®Google Scholar